Apixaban Dosing for Left Ventricular Thrombus
For left ventricular thrombus treatment, apixaban should be dosed at 10 mg twice daily for the first 7 days followed by 5 mg twice daily. 1
Dosing Recommendations
- The recommended initial treatment dose for venous thromboembolism (VTE) with apixaban is 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily 1
- This dosing regimen is appropriate for left ventricular thrombus treatment as it follows the same anticoagulation principles used for treating thrombotic conditions 1
- After 6 months of initial therapy, either continuing with 5 mg twice daily or reducing to 2.5 mg twice daily can be considered for extended treatment 1
Dose Adjustments
Dose reduction to 2.5 mg twice daily is recommended if the patient meets at least 2 of the following 3 criteria 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
For patients with severe renal impairment (CrCl <15 mL/min), apixaban should be used with caution as these patients were excluded from clinical trials 2
Clinical Evidence for LV Thrombus
- Recent randomized clinical trials have demonstrated that apixaban is non-inferior to warfarin for the treatment of left ventricular thrombus after myocardial infarction 3, 4
- In a 2023 randomized trial, apixaban 5 mg twice daily showed comparable LV thrombus resolution rates to warfarin at 3 months (76.0% vs 80.0%, p<0.036 for non-inferiority) 3
- Another prospective multicenter trial showed that apixaban achieved complete thrombus resolution in 16 of 17 patients (94.1%) compared to 14 of 15 patients (93.3%) with warfarin at 3 months 4
- Case reports have documented successful resolution of LV thrombi with apixaban, with resolution times ranging from 7 to 28 days (mean: 17 days) 5, 6
Safety Considerations
- Apixaban has demonstrated a favorable bleeding profile compared to warfarin in clinical trials 7
- In patients with LV thrombus, apixaban was associated with fewer major bleeding events compared to warfarin in clinical studies 3, 4
- Patients using apixaban required shorter hospital stays and fewer outpatient visits compared to those on warfarin therapy 3
Common Pitfalls and Caveats
- Do not confuse the dosing for atrial fibrillation (5 mg twice daily standard dose) with the initial VTE treatment dosing (10 mg twice daily for 7 days, then 5 mg twice daily) 1
- Ensure proper assessment of renal function before initiating therapy, as dose adjustments are needed for patients with significant renal impairment 2
- Be aware that concomitant antiplatelet therapy increases bleeding risk, which is particularly relevant in post-MI patients who may require dual antiplatelet therapy 8
- Monitor for drug interactions, particularly with strong dual inhibitors of CYP3A4 and P-glycoprotein, which may require dose adjustment 1